FDA greenlights test to detect sepsis-causing bacteria in blood

Mackenzie Bean - Print  | 

The FDA granted market clearance to T2 Biosystems' test to detect sepsis-causing bacterial pathogens in blood samples, the company announced May 29.

The T2Bacteria Panel can identify the following types of sepsis-causing bacteria species:

Most diagnostic tests for bacteria in the blood require a positive blood culture sample before a bacteria species can be identified, which can postpone results by one to five days. However, the T2Bacteria Panel can achieve results in about five hours.

"The FDA's market clearance of the T2Bacteria Panel is a significant milestone for our company, but more importantly, for millions of patients at risk of sepsis from bloodstream infections," said John McDonough, president and CEO of T2 Biosystems. "This breakthrough technology provides potentially life-saving answers for patients and economic savings to hospitals that bear the enormous burden of sepsis-related care and mortality."

More articles on supply chain:

How Mass General is dealing with the worst opioid shortage in years: 7 things to know
90% of ER physicians had shortages of critical medicine in the last month: 5 notes
Red Cross offers blood donors $5 Amazon gift card to boost summer donations

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.